Clinical Validity of IntelliSpace Cognition Digital Assessment Platform in Mild Cognitive Impairment

AO_SCPLOWBSTRACTC_SCPLOWWe evaluated a digital cognitive assessment platform, Philips IntelliSpace Cognition, in a cross-sectional cohort of patients diagnosed with mild cognitive impairment (MCI). Performance on individual neuropsychological tests, cognitive domain scores, and Alzheimers disease (AD) specific composite scores in MCI were compared with a cohort of cognitively normal adults (CN). The cohorts were matched for age, sex, and education. The performance on all but two neuropsychological tests was worse in the MCI group. After ranking the cognitive domains by effect size, we found that the memory domain was most impaired, followed by executive functioning. The Early AD/MCI Alzheimers Cognitive Composite (EMACC) and Preclinical Alzheimers Cognitive Composite (PACC) scores were constructed from the digital tests on Philips IntelliSpace Cognition. Both AD-specific composite scores showed greater sensitivity and specificity than the Mini-Mental State Examination, as well as individual neuropsychological tests and individual cognitive domain scores. Together, these results demonstrate the diagnostic value of Philips IntelliSpace Cognition in patients with MCI.